BioCentury
ARTICLE | Company News

Fibrocell, MIT, University of California deal

May 21, 2012 7:00 AM UTC

Fibrocell acquired rights to commercialize discoveries resulting from a 2011 deal with the university to research the conversion of dermal fibroblasts into pure functional human cell types for potential use in personalized medicine for illnesses including Parkinson's disease (PD), diabetes and heart disease. Under the 2011 deal, Fibrocell is providing UCLA with its cell multiplication and expansion technology to research diagnostics or treatments based on patients' own cells, as well as funding (see BioCentury, March 14, 2011). ...